$108 Million

Surface Oncology

Initial Public Offering

Bookrunner, April 2018

Surface is an immune-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME), for the development of next generation cancer therapies.